{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:34:39Z","timestamp":1789940079568,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T00:00:00Z","timestamp":1445817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>X\u2010linked hypophosphatemia (XLH) is an inherited metabolic bone disease with abnormally elevated serum FGF23 resulting in low renal maximum threshold for phosphate reabsorption, low serum phosphate (Pi) and 1,25\u2010dihydroxyvitamin D levels with subsequent development of short stature and skeletal deformities. KRN23 is a novel human anti\u2010FGF23 antibody for the treatment of XLH. The pharmacokinetics (PK) and pharmacodynamics (PD) models of KRN23 were assessed following subcutaneous dosing every 28 days over an initial 4\u2010month dose escalation (0.05\u20130.6\u2009mg\/kg) and a subsequent 12\u2010month titration period (0.1\u20131.0\u2009mg\/kg) in XLH adults. The PK of KRN23 was described by a 1\u2010compartmental model with first\u2010order absorption and elimination at doses \u22650.1\u2009mg\/kg. The elimination half\u2010life was 17.8 days. Covariates did not affect KRN23 PK. Mean peak serum Pi was attained 7\u201310 days after dosing and progressively increased following each of the initial 4 doses with comparable peak values attained following the sixth through tenth doses with a slight decrease thereafter. A PK\u2010PD model with a maximum effect (E<jats:sub>max<\/jats:sub>) and a time\u2010varying effective concentration to reach 50% of E<jats:sub>max<\/jats:sub> (EC<jats:sub>50,t<\/jats:sub>) described data adequately. Typical E<jats:sub>max<\/jats:sub> was 1.5\u2009mg\/dL. Typical EC<jats:sub>50,t<\/jats:sub> was 1780\u2009ng\/mL and 5999\u2009ng\/mL after first and last dose, respectively.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcph.611","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T13:09:01Z","timestamp":1438866541000},"page":"429-438","source":"Crossref","is-referenced-by-count":24,"title":["Population pharmacokinetic and pharmacodynamic analyses from a 4\u2010month intradose escalation and its subsequent 12\u2010month dose titration studies for a human monoclonal anti\u2010FGF23 antibody (KRN23) in adults with X\u2010linked hypophosphatemia"],"prefix":"10.1002","volume":"56","author":[{"given":"Xiaoping","family":"Zhang","sequence":"first","affiliation":[{"name":"Kyowa Hakko Kirin Pharma Inc Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peyret","sequence":"additional","affiliation":[{"name":"Pharsight\u2010A Certara\u2122 Company Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie H.","family":"Gosselin","sequence":"additional","affiliation":[{"name":"Pharsight\u2010A Certara\u2122 Company Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Marier","sequence":"additional","affiliation":[{"name":"Pharsight\u2010A Certara\u2122 Company Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Imel","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Yale Center for X\u2010Linked Hypophosphatemia Yale University School of Medicine New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(64)90085-3"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005050573"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007010068"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1768"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.102"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90742.2008"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-4217-5_24"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010303031802"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-52-3-463"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111900"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650070602"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080417"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090509"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72829"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1551"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.570"},{"key":"e_1_2_9_19_1","unstructured":"R Core Team. 2013. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.http:\/\/www.R\u2010project.org\/. Accessed on July 26 2015."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/11537430-000000000-00000"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100241"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021105"},{"key":"e_1_2_9_23_1","unstructured":"Investigator Laboratory Instruction Manual. Quest Diagnostics Clinical Trials. 27027 Tourney Suite 2E Valencia CA 91355."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92736-1"},{"key":"e_1_2_9_25_1","unstructured":"Investigator Laboratory Instruction Manual. Cranford NJ: Esoterix Clinical Trials Services A Division of LabCorp."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03638-X"},{"issue":"3","key":"e_1_2_9_27_1","first-page":"17","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) following four monthly doses of a human monoclonal anti\u2010FGF23 (fibroblast growth factor 23) antibody (KRN23) in adults with X\u2010linked hypophosphatemia (XLH)","volume":"35","author":"Zhang X","year":"2014","journal-title":"Endocr Rev"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.611","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.611","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.611","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T08:02:41Z","timestamp":1694160161000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,26]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1002\/jcph.611"],"URL":"https:\/\/doi.org\/10.1002\/jcph.611","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,26]]}}}